IMR Press / FBL / Special Issues / 1408364744460914689

MAPKs and Oncogenesis

Submission deadline: 01 January 2022
Special Issue Editor
Guan Chen, MD
Department of Pharmacology and Toxicology Medical College of Wisconsin, 8701 Watertown Plank Road Milwaukee, WI 53226, USA
Interests: p38MAPKs; Ras oncogene; Signal transduction; Nuclear receptors; Colon; Pancreatic and breast cancer
Special Issue and Collections in IMR journals
Special Issue Information

Dear Colleagues,

Kinases can amplify oncogenic signals by phosphorylating substrates and thereby play a decisive role in oncogenesis. Deregulated kinases in cancer are druggable and represent attractive targets for therapeutic intervention, and their precise roles in oncogenesis, however, are mostly not well-established. Mitogen-activated protein kinases (MAPKs) play a fundamental role in relaying and processing extracellular and intracellular signals to regulate cell growth, cell death and cell transformation through substrates, target genes, interacting partners, and cross-talking with other pathways. For example, extracellular-signal regulated kinases (ERKs) are major proliferative pathways for Ras and other oncogenes, whereas p38 and c-Jun N-terminal kinases (JNKs) are activated by stress signaling and inflammation stimulus and can either promote or inhibit inflammation-associated cancer. Recent genetic studies show that p38 MAPK family proteins play a cell-type dependent and isoform-specific role in inflammation and in inflammation-associated cancer. This knowledge is critical for understanding basic mechanisms of oncogenesis and is fundamentally important for precision oncology. This special issue aims to update recent developments in the field of MAPKs and oncogenesis and discuss potential approaches to effectively intervene tumorigenesis by targeting a specific MAPK pathway.

Prof. Guan Chen, MD, PhD

Guest Editor

Inflammation-associated Cancer
Target Therapy
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (3 Papers)
Open Access Review
Expression of Novel Kinase MAP3K19 in Various Cancers and Survival Correlations
Khoa Nguyen, Hassan Yousefi, Thomas Cheng, Justin Magrath, ... Matthew E. Burow
Front. Biosci. (Landmark Ed) 2022, 27(6), 196;
(This article belongs to the Special Issue MAPKs and Oncogenesis)
Open Access Review
MAP3K Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types
Khoa Nguyen, Minh N. Tran, Andrew Rivera, Thomas Cheng, ... Matthew E. Burow
Front. Biosci. (Landmark Ed) 2022, 27(5), 167;
(This article belongs to the Special Issue MAPKs and Oncogenesis)
Open Access Review
MAPK and β-Catenin signaling: implication and interplay in orthodontic tooth movement
Jiawen Yong, Sabine Groeger, Joerg Meyle, Sabine Ruf
Front. Biosci. (Landmark Ed) 2022, 27(2), 54;
(This article belongs to the Special Issue MAPKs and Oncogenesis)
Back to top